About Us Our Values Portfolio Contact SUBMIT Menu Home | Company | GEM Pharmaceuticals COMPANY PROFILE: GEM PHARMACEUTICALS LEADERSHIP Arthur Klausner, Chief Executive Officer Gerald M. Walsh, Ph.D., President and COO Richard D. Olson, Ph.D., Chief Science Officer Gem Pharmaceuticals is a clinical-stage biopharmaceutical company developing proprietary anthracycline derivatives specifically designed to eliminate the critical cardiotoxicity side effect of this powerful class of chemotherapeutics while maintaining their well-documented anti-cancer efficacy. In so doing, Gem effectively transforms traditional broad-spectrum cytotoxic drugs into modern – and biochemically targeted – anti-cancer agents that hold the potential for higher dosing and correspondingly improved therapeutic utility. Hendricks Holding Co. is a significant investor in Gem. "Our Phase 2 clinical study in sarcoma patients is designed to confirm that GPX-150 is less toxic than doxorubicin, and also to demonstrate that the ability to dose GPX-150 for a longer period of time than dox will potentially allow for improved efficacy in this difficult-to-treat, orphan-sized cancer population.” — Arthur Klausner, CEO GEM Pharmaceuticals 941 Lake Forest Circle Birmingham, AL 35244 690 Third Street, Suite 300, Beloit, WI 53511 | T 608 362-8000 | F 608 361-0860 Privacy Statement | Terms Of Use | Login